MLchartDataset catalogue

Abiraterone decanoate depot

Term · Oncology and biomedicine · MLC-T-ONC-009581

A depot formulation containing the decanoate ester of abiraterone, a steroidal compound with antiandrogen activity. Upon administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This suppresses testosterone production by both the testes and the adrenals to castrate-range levels. This may decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells.

Table 1. Record
IdentifierMLC-T-ONC-009581
FieldOncology and biomedicine
SynonymsPRL-02 depot
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-009581",
  "term": "Abiraterone decanoate depot",
  "field": "Oncology and biomedicine",
  "definition": "A depot formulation containing the decanoate ester of abiraterone, a steroidal compound with antiandrogen activity. Upon administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This suppresses testosterone production by both the testes and the adrenals to castrate-range levels. This may decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells.",
  "synonyms": [
    "PRL-02 depot"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/abiraterone-decanoate-depot/"
}

Record 177 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.